Mesoblast Profit Margin

The latest profit margin for MESO is -144.33% as of December 2025. That compares with -1822.77% in the prior-year period — up 92.1% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Mesoblast's historical trend and sector peers before judging valuation or financial health.

Over the past year, MESO's profit margin moved from -1822.77% to -144.33% — a 92.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mesoblast's valuation or profitability profile.

Against Healthcare companies, MESO currently prints -144.33% for profit margin, while the sector average sits near 15.58%. That is roughly 1026.2% below the sector mean. Large gaps often invite a closer look at Mesoblast's growth, margins, and balance sheet.

Profit Margin shows how effectively Mesoblast converts resources into returns. At -144.33%, MESO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1822.77% in the prior-year period — up 92.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MESO's profit margin (-144.33%), review year-over-year change from -1822.77%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.